n°218

September 2020

Issue Contents
Editorial

Free  Evidence required: for covid-19 too

p.199

Marketing Authorisations

Apalutamide (Erleada°) and non-metastatic prostate cancer

p.201-203
Delayed appearance of metastases in case of castration-resistant disease

Enzalutamide (Xtandi°) and non-metastatic, castration-resistant prostate cancer

p.203-204

Cannabidiol (Epidyolex°) in certain severe forms of childhood epilepsy

p.205-207
An option to consider, but liver function must be monitored

Melatonin (Slenyto°) for sleep disorders in children with autism

p.208-209

INN Common stem: -lutamide

p.209

Adverse Effects

Drug-induced priapism

p.210-213

Inset. Priapism, in brief

p.212

Free  VEGF inhibitors: arterial aneurysm and dissection

p.214

Nasal fentanyl: fatal confusion with a spray for the common cold

p.215

Ingenol mebutate: skin cancers

p.215

Ulipristal 5 mg: marketing authorisation suspended in the European Union

p.216

Pregabalin, gabapentin: respiratory depression

p.216

Reviews

Treatment of mild asthma

p.217
An inhaled beta-2 agonist during exacerbations, possibly combined with an as-needed inhaled corticosteroid

 Queries and Comments. Proton pump inhibi­tors (PPIs) in infants: what is the harm-benefit balance?

p.218-219

Outlook

Drug shortages: report the sometimes-serious adverse events they cause

p.220-222

Clinical trials: insufficiently rigorous requirements for comparators

p.222

A patent on Kymriah° successfully challenged by nonprofit organisations

p.222

Shedding light on financial links in Switzerland

p.223

Alemtuzumab in multiple sclerosis: half-measures

p.223

Masthead

Free  Masthead

p.198

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe